2-(Dicyclohexylphosphino)-2'-(dimethylamino)biphenyl → N-{3-(cis-3,5-Dimethyl-1-piperazinyl)-4-[(trifluoromethyl)oxy]phenyl}-4-(2-thienyl)benzenesulfonamide
反応式
Br[C:2]1[CH:3]=[C:4]([NH:13][S:14]([C:17]2[CH:22]=[CH:21][C:20]([C:23]3[S:24][CH:25]=[CH:26][CH:27]=3)=[CH:19][CH:18]=2)(=[O:16])=[O:15])[CH:5]=[CH:6][C:7]=1[O:8][C:9]([F:12])([F:11])[F:10].[CH3:28][C@H:29]1[CH2:34][NH:33][CH2:32][C@@H:31]([CH3:35])[NH:30]1.CC(C)([O-])C.[Na+].C1(P(C2CCCCC2)C2C=CC=CC=2C2C=CC=CC=2N(C)C)CCCCC1>O1CCOCC1.C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.[Pd].[Pd]>[CH3:28][C@H:29]1[NH:30][C@@H:31]([CH3:35])[CH2:32][N:33]([C:2]2[CH:3]=[C:4]([NH:13][S:14]([C:17]3[CH:22]=[CH:21][C:20]([C:23]4[S:24][CH:25]=[CH:26][CH:27]=4)=[CH:19][CH:18]=3)(=[O:16])=[O:15])[CH:5]=[CH:6][C:7]=2[O:8][C:9]([F:12])([F:11])[F:10])[CH2:34]1参加物
7
反応物 4
生成物 1
試薬・触媒・溶媒 2
実験手順
The product of Step 2 (162 mg, 0.34 mmol), cis-2,6-dimethyl piperazine (78 mg, 0.68 mmol), sodium tert-butoxide (169 mg, 0.68 mmol), tris(dibenzylideneacetone)dipalladium(0) (16 mg, 0.017 mmol) and 2-dicyclohexylphosphino-2′-(N,N-dimethylamino)biphenyl (20 mg, 0.051 mmol) in dioxane (4 ml) were heated in a microwave reactor at 125° C. for 30 minutes. The reaction mixture was applied to an SCX ion exchange cartridge (Varian bond-elute) and washed with methanol and 2M ammonia in methanol. The combined basic fractions were concentrated in vacuo and the residue purified by mass directed autoprep HPLC to afford the title compound (E245). MS (ES+) m/e 512 [M+H]+.
後処理
- washThe reaction mixture was applied to an SCX ion exchange cartridge (Varian bond-elute)
- washwashed with methanol and 2M ammonia in methanol
- concentrationThe combined basic fractions were concentrated in vacuo
- customthe residue purified by mass
出典と根拠
- ORDレコード
- ord-6c0eb222b8b44af7b6c2cde901ab3206
- 出典データセット
- uspto-grants-2008_06
- 特許番号
- US07381728B2
反応ノート
読み込み中…